Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Peuler JD, Phelps LE.

J Smooth Muscle Res. 2015;51:22-36. doi: 10.1540/jsmr.51.22.

2.

Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes.

Parati G, Ochoa JE, Salvi P, Lombardi C, Bilo G.

Diabetes Care. 2013 Aug;36 Suppl 2:S312-24. doi: 10.2337/dcS13-2043. Review. No abstract available.

3.

PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Huang JV, Greyson CR, Schwartz GG.

J Lipid Res. 2012 Sep;53(9):1738-54. doi: 10.1194/jlr.R024505. Epub 2012 Jun 8. Review.

4.

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

Carta AR, Pisanu A, Carboni E.

Parkinsons Dis. 2011;2011:689181. doi: 10.4061/2011/689181. Epub 2011 Mar 29.

5.

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group..

Clin J Am Soc Nephrol. 2011 May;6(5):1032-40. doi: 10.2215/CJN.09291010. Epub 2011 Mar 31.

6.

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD.

Eur Heart J. 2010 Apr;31(7):824-31. doi: 10.1093/eurheartj/ehp604. Epub 2010 Jan 29.

7.

Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats.

Sartori-Valinotti JC, Venegas-Pont MR, Lamarca BB, Romero DG, Yanes LL, Racusen LC, Jones AV, Ryan MJ, Reckelhoff JF.

Steroids. 2010 Nov;75(11):794-9. doi: 10.1016/j.steroids.2009.10.010. Epub 2009 Oct 31.

8.

Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes?

Parati G, Bilo G.

Diabetes Care. 2009 Nov;32 Suppl 2:S298-304. doi: 10.2337/dc09-S326. Review. No abstract available.

9.

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Fisman EZ, Tenenbaum A.

Cardiovasc Diabetol. 2009 Jul 20;8:38. doi: 10.1186/1475-2840-8-38. Review.

10.

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.

Cardiovasc Diabetol. 2009 Feb 26;8:12. doi: 10.1186/1475-2840-8-12.

11.

Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.

Venegas-Pont M, Sartori-Valinotti JC, Maric C, Racusen LC, Glover PH, McLemore GR Jr, Jones AV, Reckelhoff JF, Ryan MJ.

Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1282-9. doi: 10.1152/ajpregu.90992.2008. Epub 2009 Feb 4.

12.

The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus.

Wieczorek A, Rys P, Skrzekowska-Baran I, Malecki M.

Rev Diabet Stud. 2008 Fall;5(3):128-35. doi: 10.1900/RDS.2008.5.128. Epub 2008 Nov 10.

Supplemental Content

Support Center